{"preliminary_commentary":{"by_channel":{"x_thread":27,"youtube":10,"podcast":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03401788\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["belzutifan"]],"indication":"von Hippel-Lindau disease-associated renal cell carcinoma","name":"LITESPARK-004","nct_id":"NCT03401788","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=litespark-004-nct03401788. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants receive 120 mg belzutifan orally once daily. Participants may continue to receive belzutifan in the absence of unacceptable treatment related toxicity or unequivocal disease progression.","label":"Open Label Belzutifan","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-04-29","type":"ESTIMATED"},"conditions":["VHL - Von Hippel-Lindau Syndrome","VHL Gene Mutation","VHL Syndrome","VHL Gene Inactivation","VHL-Associated Renal Cell Carcinoma","VHL-Associated Clear Cell Renal Cell Carcinoma"],"enrollment":{"count":50,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Belzutifan","otherNames":["PT2977","MK-6482","WELIREG™"],"type":"DRUG"}],"last_update":"2026-04-13","lead_sponsor":"Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","official_title":"An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-04-29","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR) in VHL Disease-Associated RCC Tumors","timeFrame":"Up to approximately 4 years"}],"references":[{"citation":"Iliopoulos O, Iversen AB, Narayan V, Maughan BL, Beckermann KE, Oudard S, Else T, Maranchie JK, Goldberg CM, Fu W, Perini RF, Liu Y, Linehan WM, Srinivasan R, Jonasch E. Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2024 Oct;25(10):1325-1336. doi: 10.1016/S1470-2045(24)00389-9. Epub 2024 Sep 13.","pmid":"39284337","type":"RESULT"},{"citation":"Srinivasan R, Iliopoulos O, Beckermann KE, Narayan V, Maughan BL, Oudard S, Else T, Maranchie JK, Iversen AB, Cornell J, Perini RF, Liu Y, Linehan WM, Jonasch E. Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study. Lancet Oncol. 2025 May;26(5):571-582. doi: 10.1016/S1470-2045(25)00099-3. Epub 2025 Apr 12.","pmid":"40228516","type":"DERIVED"},{"citation":"Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. doi: 10.1056/NEJMoa2103425.","pmid":"34818478","type":"DERIVED"}],"start_date":{"date":"2018-05-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)","url":"https://clinicaltrials.gov/study/NCT03401788"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/litespark-004-nct03401788"}